Tumour marker measurements in the diagnosis and monitoring of breast cancer
- 30 April 2000
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 26 (2), 91-102
- https://doi.org/10.1053/ctrv.1999.0151
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- British Association of Surgical Oncology Guidelines: The management of metastatic bone disease in the United KingdomEuropean Journal of Surgical Oncology, 1999
- The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markersEuropean Journal Of Cancer, 1999
- CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative studyEuropean Journal Of Cancer, 1995
- Tumour marker CA15-3: possible uses in the routine management of breast cancerEuropean Journal Of Cancer, 1995
- Immunodiagnosis of TumoursEuropean Journal Of Cancer, 1993
- Prospective assessment of the role of five tumour markers in breast cancerCancer Immunology, Immunotherapy, 1991
- Assessment of four monoclonal antibodies as serum markers in breast cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Comparison of breast cancer mucin (BCM) and CA 15-3 in human breast cancerBreast Cancer Research and Treatment, 1990
- Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseasesBreast Cancer Research and Treatment, 1989
- High molecular weight epithelial mucins as markers in breast cancerEuropean Journal of Cancer and Clinical Oncology, 1988